Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corcept Therapeutics (CORT) Other Accumulated Expenses: 2009-2025

Historic Other Accumulated Expenses for Corcept Therapeutics (CORT) over the last 8 years, with Sep 2025 value amounting to $28.3 million.

  • Corcept Therapeutics' Other Accumulated Expenses rose 2.11% to $28.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $28.3 million, marking a year-over-year increase of 2.11%. This contributed to the annual value of $33.9 million for FY2024, which is 58.78% up from last year.
  • According to the latest figures from Q3 2025, Corcept Therapeutics' Other Accumulated Expenses is $28.3 million, which was down 2.50% from $29.0 million recorded in Q2 2025.
  • In the past 5 years, Corcept Therapeutics' Other Accumulated Expenses ranged from a high of $33.9 million in Q4 2024 and a low of $12.4 million during Q4 2021.
  • For the 3-year period, Corcept Therapeutics' Other Accumulated Expenses averaged around $25.3 million, with its median value being $24.9 million (2024).
  • Data for Corcept Therapeutics' Other Accumulated Expenses shows a peak YoY surged of 58.78% (in 2024) over the last 5 years.
  • Corcept Therapeutics' Other Accumulated Expenses (Quarterly) stood at $12.4 million in 2021, then grew by 17.13% to $14.6 million in 2022, then surged by 46.37% to $21.3 million in 2023, then spiked by 58.78% to $33.9 million in 2024, then increased by 2.11% to $28.3 million in 2025.
  • Its Other Accumulated Expenses stands at $28.3 million for Q3 2025, versus $29.0 million for Q2 2025 and $33.9 million for Q4 2024.